3Grant LM, Lisker-Melman M. Nonalcoholic fatty liver disease. Ann Hepatol, 2004, 3: 93-99.
4Bugianesi E, Marzocchi R, Villanova N, et al. Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): treatment. Best Pract Res Clin Gastroenterol, 2004, 18:1105-1116.
5Fasshauer M, Paschke R, Stumvoll M. Adiponectin, obesity, and cardiovascular disease.Biochimie, 2004, 86: 779-784.
6Roberts EA. Steatohepatitis in children. Best Pract Res Clin Gastroenterol,2002, 16: 749-765.
7Loguercio C, De Girolamo V, de Sio I, et al. Non-alcoholic fatty liver disease in an area of southern Italy: main clinical, histological, and pathophysiological aspects. J Hepatol, 2001,35: 568-574.
8Asayama K, Hayashibe H, Dobashi K, et al. Decrease in serum adiponectin level due to obesity and visceral fat accumulation in children. Obes Res,2003, 11: 1072-1079.
9Hui JM, Hodge A, Farrell GC, et al. Beyond insulin resistance in NASH:TNF-alpha or adiponectin? Hepatology, 2004, 40: 46-54.
10Ding WX, Yin XM. Dissection of the multiple mechanisms of TNF-al-pha-induced apoptosis in liver injury. J Cell Mol Med, 2004, 8: 445-454.
2Fatty Liver and Alcoholic Liver Disease Study Group of the Chinese Liver Disease Association..非酒精性脂肪性肝病诊疗指南[J].中华肝脏病杂志,2006,14(3):161-163. 被引量：1511
3OLSSON M L,CLAUSEN H. Modifying the red cell sur- face:towards an ABO-universal blood supply [J]. Br J Haematol, 2008,140( 1 ) : 3- 12.
4HAFFNER S M,GONZALEZ C, M IETHNEN H, et al. A prospective analysis of the HOMA model. The Mecico City diabetes study[J]. Diabetes Care, 1996, 19(10) : 1 138-- 1 141.
5KANG Y J. Copper and homocysteine in cardiovascular di- seases [ J ]. Pharmacol Ther, 2011,12 (3):321-331.
6LEE R,FRENKEL E P. Hyperhomocysteinemia and thro- mbosis [J]. Hematol Oncol Clin North Am,2003,17(1 ): 85-- 102.
7BANOS-GONZALEZ M A,ANGLES-CANO E,CAR- DOSO-SALDANA G,et al. Lipoprotein(a) and homoc - ysteine potentiate the risk of coronary artery disease in male[J]. Circ J,2012,76(8): 1 953-- 1 957.
8KOKTURK N,KANBAY A,AYDOGDU M, et al. Hyper- homocysteinemia prevalence among patients with venous thromboembolism [J ]. Clin Appl Thromb Hemost,2011, 17(5):487-493.
9GOTI'SATER A, FORSBLAD J, MATHASSON I, et al. D- ecreasing plasma endothelin-1 and unchanged plasma neopterin during folate supplementation in hyperhomocys- teinemia[ J ]. Int Angiol, 2002,21 (2) : 158-- 164.
10GOLBAHAR J,AMINZADEH M A, KASSAB S E, et al. Hyperhomocysteinemia induces insulin resistance in male Sprague-Dawley rats [J]. Diabetes Res Clin Pract, 2007,76(1 ) : 1--5.
